Apellis Pharmaceuticals, Inc.APLSNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+158.6%
5Y CAGR+44.6%
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

3Y CAGR
+158.6%/yr
Annual compound
5Y CAGR
+44.6%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
6.3x
Strong expansion
Streak
2 yr
Consecutive growthAccelerating
PeriodValue
2025151.59%
202485.23%
2023-15.76%
20228.77%
2021-250.88%
202023.99%
2019-60.88%
2018-181.66%
2017-79.19%
2016-37.90%